Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Research — Stock-based compensation expense by Quarter
Research — Stock-based compensation expense ($M) ($M)
Vertex Pharmaceuticals Research — Stock-based compensation expense: $21.2M in Q2 2026, down 5.8% from a year earlier.
Where the Q2 2026 figure comes from
“|| Stock-based compensation expense | 21.2 | 22.5 | (6)% | 42.4 | 44.8 | (5)%”
Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K MD&A (Research Expenses Disaggregation Table).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Research — Stock-based compensation expense ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-sbc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.